Purdue and Mallinckrodt resolve OxyContin patent suit
This article was originally published in Scrip
Purdue Pharma and Mallinckrodthave signed an agreement to end their OxyContin (oxycodone controlled-release) tablets patent infringement suit which has been pending in a district court in New York. Mallinckrodt acknowledges the validity and enforceability of Purdue's patents. At the same time, Purdue has agreed to grant Mallinckrodt a royalty-bearing licence to sell limited quantities of versions of 10mg, 20mg, 40mg and 80mg extended-release oxycodone tablets. The District Court for the Southern District of New York has repeatedly ruled in favour of Purdue on the enforceability of its US patents covering OxyContin.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.